Fulgent Genetics, Inc. (FLGT)Healthcare | Diagnostics & Research | El Monte, United States | NasdaqGM
19.81 USD
-1.53
(-7.170%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 19.81 |
Hot Take ↕ | Oct. 10, 2026, 10:06 a.m. EDT
The investment case here is fundamentally broken. The company is burning cash aggressively, with operating cash flow and free cash flow both deeply negative, while returning losses to shareholders via dilution rather than dividends. The balance sheet, though currently showing low debt relative to equity, is propped up by a cash pile that is being consumed faster than it can be replenished. Revenue growth is a mere 4.4%, which is insufficient to offset the massive operational bleed. The market has already priced this reality in; the stock trades at a fraction of book value because investors see a value trap, not a bargain. The recent news of mixed analyst targets and margin questions confirms that the business model is under severe stress. While management moves keep some bulls hopeful, the financials tell a story of deterioration. The options market agrees with the pessimists, betting heavily on further declines. This is a 'avoid' situation where the pain of holding will likely outweigh any potential recovery until the bleeding stops. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.135874 |
| AutoARIMA | 0.137500 |
| AutoETS | 0.137506 |
| AutoTheta | 0.138101 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 6.89 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.337 |
| Excess Kurtosis | -1.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.964 |
| Revenue per Share | 10.744 |
| Market Cap | 545,077,888 |
| Forward P/E | -14.36 |
| Beta | 0.93 |
| Profit Margins | -26.05% |
| Website | https://www.fulgentgenetics.com |
As of Oct. 10, 2026, 10:06 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (over 300 contracts vs less than 100 in calls) and elevated implied volatility on put strikes. The strike distribution shows significant concentration at the $20 level, suggesting a high probability of a drop below current prices within the next few months. Conversely, call activity is sparse and skewed toward deep out-of-the-money strikes, indicating limited bullish conviction despite some speculative interest in a recovery to $30.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.059082866 |
| Address1 | 4,399 Santa Anita Avenue |
| All Time High | 189.89 |
| All Time Low | 2.725 |
| Ask | 23.05 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 287,540 |
| Average Daily Volume3 Month | 300,575 |
| Average Volume | 300,575 |
| Average Volume10Days | 287,540 |
| Beta | 0.933 |
| Bid | 18.53 |
| Bid Size | 1 |
| Board Risk | 9 |
| Book Value | 36.403 |
| City | El Monte |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 19.81 |
| Current Ratio | 6.338 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 21.49 |
| Day Low | 19.75 |
| Debt To Equity | 0.964 |
| Display Name | Fulgent Genetics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,914,200 |
| Earnings Call Timestamp Start | 1,793,914,200 |
| Earnings Timestamp | 1,793,908,800 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -89,461,000 |
| Ebitda Margins | -0.27617002 |
| Enterprise To Ebitda | -3.735 |
| Enterprise To Revenue | 1.031 |
| Enterprise Value | 334,114,368 |
| Eps Current Year | -2.27 |
| Eps Forward | -1.38 |
| Eps Trailing Twelve Months | -2.81 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 626 454 1667 |
| Fifty Day Average | 20.4364 |
| Fifty Day Average Change | -0.6264 |
| Fifty Day Average Change Percent | -0.030651191 |
| Fifty Two Week Change Percent | -5.9082866 |
| Fifty Two Week High | 31.04 |
| Fifty Two Week High Change | -11.230001 |
| Fifty Two Week High Change Percent | -0.36179128 |
| Fifty Two Week Low | 13.46 |
| Fifty Two Week Low Change | 6.3499994 |
| Fifty Two Week Low Change Percent | 0.47176817 |
| Fifty Two Week Range | 13.46 - 31.04 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,475,155,800,000 |
| Float Shares | 16,691,052 |
| Forward Eps | -1.38 |
| Forward P E | -14.355072 |
| Free Cashflow | -90,904,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1,315 |
| Fullday Change | -1.5300007 |
| Fullday Change Percent | -7.169637 |
| Fullday Price | 19.81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.35582 |
| Gross Profits | 115,263,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.37747002 |
| Held Percent Institutions | 0.58303 |
| Implied Shares Outstanding | 27,515,293 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California. |
| Long Name | Fulgent Genetics, Inc. |
| Market | us_market |
| Market Cap | 545,077,888 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_315621345 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -84,382,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 585,250,282 |
| Number Of Analyst Opinions | 1 |
| Open | 21.45 |
| Operating Cashflow | -83,697,000 |
| Operating Margins | -0.39351 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 626 350 0537 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 19.81 |
| Post Market Time | 1,792,180,874 |
| Previous Close | 21.34 |
| Price Eps Current Year | -8.726872 |
| Price Hint | 2 |
| Price To Book | 0.5441859 |
| Price To Sales Trailing12 Months | 1.6826923 |
| Profit Margins | -0.26049 |
| Quick Ratio | 4.565 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.5300007 |
| Regular Market Change Percent | -7.1696377 |
| Regular Market Day High | 21.49 |
| Regular Market Day Low | 19.75 |
| Regular Market Day Range | 19.75 - 21.49 |
| Regular Market Open | 21.45 |
| Regular Market Previous Close | 21.34 |
| Regular Market Price | 19.81 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 443,163 |
| Return On Assets | -0.06296 |
| Return On Equity | -0.081099994 |
| Revenue Growth | 0.044 |
| Revenue Per Share | 10.744 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 27,515,293 |
| Shares Percent Shares Out | 0.0813 |
| Shares Short | 2,238,210 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,368,385 |
| Short Name | Fulgent Genetics, Inc. |
| Short Percent Of Float | 0.1306 |
| Short Ratio | 6.68 |
| Source Interval | 15 |
| State | CA |
| Symbol | FLGT |
| Target High Price | 19.0 |
| Target Low Price | 19.0 |
| Target Mean Price | 19.0 |
| Target Median Price | 19.0 |
| Total Cash | 257,032,000 |
| Total Cash Per Share | 9.341 |
| Total Debt | 9,603,000 |
| Total Revenue | 323,932,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.82 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.736 |
| Two Hundred Day Average Change | 0.073999405 |
| Two Hundred Day Average Change Percent | 0.0037494632 |
| Type Disp | Equity |
| Volume | 443,163 |
| Website | https://www.fulgentgenetics.com |
| Zip | 91,731 |